At the end of the latest market close, Iterum Therapeutics plc (ITRM) was valued at $1.23. In that particular session, Stock kicked-off at the price of $1.20 while reaching the peak value of $1.21 and lowest value recorded on the day was $1.12. The stock current value is $1.17.
Recently in News on April 6, 2021, Iterum Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference. Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that Corey Fishman, Chief Executive Officer, will provide a company overview and business update at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, at 3:45p.m. ET. You can read further details here
Iterum Therapeutics plc had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.9950 on 02/11/21, with the lowest value was $0.9301 for the same time period, recorded on 04/16/21.
Iterum Therapeutics plc (ITRM) full year performance was -68.38%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Iterum Therapeutics plc shares are logging -80.56% during the 52-week period from high price, and 159.42% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.45 and $6.02.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 6451838 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Iterum Therapeutics plc (ITRM) recorded performance in the market was 18.30%, having the revenues showcasing -24.52% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 202.80M, as it employees total of 7 workers.
Market experts do have their say about Iterum Therapeutics plc (ITRM)
During the last month, 0 analysts gave the Iterum Therapeutics plc a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.4046, with a change in the price was noted +0.3480. In a similar fashion, Iterum Therapeutics plc posted a movement of +42.34% for the period of last 100 days, recording 19,238,326 in trading volumes.
Technical breakdown of Iterum Therapeutics plc (ITRM)
Raw Stochastic average of Iterum Therapeutics plc in the period of last 50 days is set at 19.04%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 33.32%. In the last 20 days, the company’s Stochastic %K was 37.03% and its Stochastic %D was recorded 38.73%.
Bearing in mind the latest performance of Iterum Therapeutics plc, several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 18.30%. Additionally, trading for the stock in the period of the last six months notably improved by 139.36%, alongside a downfall of -68.38% for the period of the last 12 months. The shares increased approximately by -7.14% in the 7-day charts and went up by -19.86% in the period of the last 30 days. Common stock shares were lifted by -24.52% during last recorded quarter.